Calcitonin concentrations in patients with chronic kidney disease and medullary thyroid carcinoma or c-cell hyperplasia

Kidney International

Volumn 70, Issue 11, 2006, Pages 2014-2020

  Borchhardt, K A ^a   Heinzl, H ^a   Gessl, A ^a   Horl W H ^a   Kaserer, K ^a   Sunder Plassmann, G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

C cell hyperplasia; Calcitonin; Chronic kidney disease; Medullary thyroid carcinoma; Pentagastrin; Receiver operating characteristic analysis

Indexed keywords

CALCITONIN; PENTAGASTRIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CALCITONIN BLOOD LEVEL; CELL HYPERPLASIA; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; CALCITONIN; CARCINOMA, MEDULLARY; FEMALE; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; PENTAGASTRIN; RENAL INSUFFICIENCY, CHRONIC; ROC CURVE; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 33845241086     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001888     Document Type: Article

References (24)

1. Zaidi M, Inzerillo AM, Moonga BS et al. Forty years of calcitonin - where are we now? A tribute to the work of Iain Macintyre, FRS. Bone 2002; 30: 655-663.
2. Vierhapper H, Raber W, Bieglmayer C et al. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 1997; 82: 1589-1593.
3. Escalada J, Teruel JL, Pavon I et al. Normal calcitonin response to pentagastrin stimulation in patients with chronic renal failure. Acta Endocrinol (Copenhagen) 1993; 129: 39-41.
4. Kotzmann H, Schmidt A, Scheuba C et al. Basal calcitonin levels and the response to pentagastrin stimulation in patients after kidney transplantation or on chronic hemodialysis as indicators of medullary carcinoma. Thyroid 1999; 9: 943-947.
5. Mulder H, Silberbusch J, Hackeng WH et al. Enhanced calcitonin release in chronic renal failure depending on the absence of severe secondary hyperparathyroidism. Nephron 1982; 31: 123-128.
6. Niccoli P, Brunet P, Roubicek C et al. Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis. Eur J Endocrinol 1995; 132: 75-81.
7. Borchhardt KA, Hörl WH, Sunder-Plassmann G. Reversibility of 'secondary hypercalcitoninemia' after kidney transplantation. Am J Transplant 2005; 5: 1757-1763.
8. Takami H. Medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocr Pathol 2003; 14: 123-131.
9. Lips CJ, Hoppener JW, Thijssen JH. Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Ann Clin Biochem 2001; 38: 168-179.
10. Massoll N, Mazzaferri EL. Diagnosis and management of medullary thyroid carcinoma. Clin Lab Med 2004; 24: 49-83.
11. Sherman SI. Thyroid carcinoma. Lancet 2003; 361: 501-511.
12. Hodak SP, Burman KD. The calcitonin conundrum - is it time for routine measurement of serum calcitonin in patients with thyroid nodules? J Clin Endocrinol Metab 2004; 89: 511-514.
13. Hegedus L. Clinical practice. The thyroid nodule. N Engl J Med 2004; 351: 1764-1771.
14. Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med 2005; 142: 926-931.
15. Karges W, Dralle H, Raue F et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004; 112: 52-58.
16. Lissak B, Baudin E, Cohen R et al. Pentagastrin testing in patients with renal insufficiency: normal responsivity of mature calcitonin. Thyroid 1998; 8: 265-268.
17. Piersanti M, Ezzat S, Asa SL. Controversies in papillary microcarcinoma of the thyroid. Endocr Pathol 2003; 14: 183-191.
18. Biscolla RP, Ugolini C, Sculli M et al. Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid 2004; 14: 946-952.
19. Levey AS. Clinical practice. Nondiabetic kidney disease. N Engl J Med 2002; 347: 1505-1511.
20. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100.
21. Bieglmayer C, Scheuba C, Niederle B et al. Screening for medullary thyroid carcinoma: experience with different immunoassays for human calcitonin. Wien Klin Wochenschr 2002; 114: 267-273.
22. Grauer A, Raue F, Ziegler R. Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin. Exp Clin Endocrinol Diabetes 1998; 106: 353-359.
23. Kaserer K, Scheuba C, Neuhold N et al. Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients. Am J Surg Pathol 2001; 25: 1245-1251.
24. Rosai M. C cell hyperplasia. In: Juan Rosai M (ed). Atlas Of The Thyroid Gland. Armed Forces Institute of Pathology: Washington DC, 1992.